With the vision to develop Nansha as a key international hub for medical and health services in Greater Bay Area, Nansha District has introduced new measures for promoting high quality development of  biomedicine industry in the free trade zone.  

Regarding biomedicine industry as a strategic driver for economic growth, Nansha aims to attract over 1,000 biomedicine enterprises by 2026, targeting an industrial scale exceeding RMB 50 billion. The focus will be on developing four advanced pharmaceutical and equipment areas, including innovative drugs, new vaccines, high-value medical consumables, and in vitro diagnostics. Additionally, Nansha will prioritize two cutting-edge technology innovations—cell and gene therapy and brain science—along with two industrial landmarks in ophthalmology and oncology.

Nansha will also  support qualified Hong Kong and Macau enterprises to conduct genetic researches. A reward will be provided to qualified foreign-invested enterprises carrying out pilot expansion in the development and application of gene diagnosis and treatment technologies. The reward is calculated at 2% of the enterprise’s actual annual foreign capital investment amount.

In recent years, Nansha has actively promoted cross-boundary medical integration. The ‘Measures for Using Hong Kong-Registered Drugs and Medical Devices in Guangdong-Hong Kong-Macao Greater Bay Area Public Hospitals’ has been officially implemented, allowing residents in the Greater Bay Area to access high-quality medical services comparable to those in Hong Kong and aligned with international standards.